In Vitro Antimicrobial Activity of Contezolid Against Mycobacterium tuberculosis and Absence of Cross-Resistance with Linezolid
2025
Li Wang | Jianxia Chen | Yifan He | Ruijuan Zheng | Jie Wang | Xiaochen Huang | Wei Sha | Lianhua Qin
Tuberculosis (TB) persists as a formidable global health threat, especially with the rising incidence of multidrug-resistant strains. This study aimed to evaluate the in vitro activity of contezolid, a novel oxazolidinone antibiotic, against Mycobacterium tuberculosis (Mtb) and assess potential cross-resistance with linezolid. Thirty-one Mtb clinical isolates (5 susceptible, 8 multidrug-resistant [MDR], 18 pre-extensively drug-resistant [pre-XDR]) were tested. Minimum inhibitory concentrations (MICs) of contezolid and linezolid were determined, along with mutation resistance frequencies. Intracellular replication inhibition in macrophages and whole-genome sequencing of resistant colonies were assessed. Cytotoxicity was evaluated via luciferase-coupled ATP assay. The MIC50 and MIC90 values of contezolid were comparable to those of linezolid. Contezolid induced higher mutation frequencies in 7 isolates. At 12 mg/L, both drugs similarly inhibited intracellular Mtb replication. Whole-genome sequencing revealed that the mce3R gene was linked to contezolid resistance, with no cross-resistance observed between two drugs. No significant cytotoxicity was observed in contezolid-treated mouse peritoneal macrophages (p >: 0.05). Contezolid exhibits anti-Mtb activity, with mce3R potentially associated with resistance. No cross-resistance with linezolid was found.
显示更多 [+] 显示较少 [-]